

## Review Article

# Genetic Polymorphisms Associated with Obesity in Southeast Asian Populations: A Systematic Review without Meta-Analysis

Ubashini VIJAKUMARAN, Nor Azian ABDUL MURAD, Muhammad Irfan ABDUL JALAL, CHIN Siok Fong, A Rahman A JAMAL, Noraidatulakma ABDULLAH

Submitted: 25 Mar 2025

Accepted: 24 Oct 2025

Online: 31 Dec 2025

UKM Medical Molecular Biology Institute (UMBI), Cheras, Kuala Lumpur, Malaysia

To cite this article: Vijakumaran U, Abdul Murad NA, Abdul Jalal MI, Chin SF, A Jamal AR, Abdullah N. Genetic polymorphisms associated with obesity in Southeast Asian populations: a systematic review without meta-analysis. *Malays J Med Sci.* 2025;**32(6)**:5–25. <https://doi.org/10.21315/mjms-03-2025-201>

To link to this article: <https://doi.org/10.21315/mjms-03-2025-201>

## Abstract

Obesity is a growing global public health challenge, with genetic factors playing a crucial role in its development. This review synthesises findings from Southeast Asian studies to investigate the association between gene polymorphisms and obesity risk across various ethnic populations. A comprehensive search of three databases, PubMed, Scopus, and Web of Science, initially retrieved 2,021 articles, from which 25 studies were meticulously selected based on stringent inclusion and exclusion criteria. The quality of the studies was assessed through the Newcastle-Ottawa Scale (NOS), a risk bias tool. These studies encompass 8,312 participants and examined 33 single nucleotide polymorphisms (SNPs). *UCP* polymorphism demonstrated a significant association with overall adiposity (OR = 2.02,  $P = 0.01$ ) in Malaysian women, while the rs659366 *UCP2* was linked to weight gain in an Indonesian cohort. *LEP* variants were not significantly associated with obesity in Malaysians, and *FTO* variants showed mixed results, with rs9939609 (OR = 3.72,  $P = 0.009$ ) and rs1421085 (OR = 3.22,  $P < 0.001$ ) variants being associated with obesity and higher body mass index (BMI) in Indonesians, but no significant findings in Malaysians. These results emphasise the genetic diversity within Southeast Asia and the challenges in replicating genetic associations across populations. To address these inconsistencies and improve our understanding of obesity in Southeast Asia, there is a pressing need for more extensive and diverse cohort studies, complemented by comprehensive genome-wide association studies (GWAS), to identify robust obesity biomarkers in Southeast Asia.

**Keywords:** obesity, overweight, gene polymorphism, single nucleotide polymorphisms, Southeast Asia

## Introduction

Obesity is a complex metabolic disorder that has become a primary global health concern, with its prevalence rising steadily across diverse populations. As of 2022, approximately one in eight people worldwide is affected by obesity. The World Health Organization (2024) (1) reports that 2.5 billion adults are overweight, and 890 million individuals are classified as obese. While environmental factors undoubtedly

play a significant role in this increase, obesity primarily results from the interplay of genetic predispositions and environmental influences. Genetic variants among individuals can affect their susceptibility and response to obesogenic environments (2). Typically, obesity is categorised into two types. Monogenic obesity is a rare condition caused solely by the impairment of genes inherited in a Mendelian pattern (3). Polygenic obesity, the more common type, results from the interaction between a myriad of

genetic polymorphisms, epigenetic regulation, and environmental factors (4). The central nervous system and neuronal pathways that modulate food intake and subsequent energy metabolism are major regulators of body fat and weight in monogenic and polygenic obesity (2). The involvement of multiple pathways in obesity (5, 6) presents significant challenges in understanding the complex mechanisms underlying the condition. One of the most studied and critical among these is the leptin-melanocortin pathway, which regulates energy metabolism through approximately 60 genes expressed in the hypothalamic region (7).

A key component of this pathway is the leptin (*LEP*) which plays a pivotal role in energy balance and appetite regulation. *LEP* is expressed in adipocytes and encodes the leptin hormone, which acts on the hypothalamus to convert proopiomelanocortin (*POMC*) into alpha-melanocyte stimulating hormone ( $\alpha$ -MSH), which suppresses appetite and food intake (8). Individuals with leptin resistance have impaired signalling in the leptin-melanocortin pathway, leading to increased food intake and reduced energy expenditure (9). Additionally, children with impaired leptin-melanocortin signalling pathways also exhibit disruptive eating patterns from early childhood, leading to severe early-onset obesity (10). Leptin regulates intracellular pathways such as *PI3K/AKT/mTOR*, *JAK2/STAT3*, and *ERK/MAPK* to control cell proliferation, differentiation, survival, migration, and invasion (11, 12). The *MAPK* pathway, including the extracellular signal-regulated kinase (*ERK*) 1/2, c-Jun N-terminal kinase (*JNK*), and *p38 MAPK*, also plays a crucial role in the pathogenesis of obesity by regulating adipogenesis, glucose homeostasis, and thermogenesis (13, 14). Notably, elevated expression of *p38 MAPK* in human adipose tissue has been linked to hypertrophic adipocytes and associated with elevated levels of insulin, glucose, and triglyceride (15).

While these signalling pathways provide important insights into the biological mechanisms of obesity, understanding the genetic underpinnings is equally critical. Advances in molecular and population-based approaches have facilitated the identification of genetic variations linked to obesity risk. Initially, gene polymorphism was explored through candidate gene studies, which later expanded into more comprehensive genome-wide association studies (GWAS) (16). The first

GWAS in 2007 reported the presence of a genetic polymorphism in the first intron of rs9930506 *FTO* that is positively associated with body mass index (BMI), ( $P = 8.6 \times 10^{-7}$ ), hip circumference (in cm) ( $P = 3.4 \times 10^{-8}$ ), and weight (in kg) ( $P = 9.1 \times 10^{-7}$ ) (17). Another GWAS comprising 38,759 participants revealed that adults with homozygous A allele at rs9939609 *FTO* weight 3 kg more than those who do not have it, with 1.67 increased odds of obesity (18). To date, GWAS studies have discovered more than 300 loci associated with obesity traits (19). However, few genes, such as *ADRB3* (20), *MCR4* (21), *BDNF* (22), *LEPR* (23), *FTO* (24), *PCKS1* (25), *CNR1* (26), and *PPARG* (27), have replicable associations with obesity (2). A large meta-analysis reported 463 signals associated with body fat in 694,649 European individuals (27). Similarly, studies in Asian populations have identified several key loci; for instance, a GWAS in Taiwan reported 13 significant SNPs, including *FTO* and *RALGAP1*, in 6,546,460 individuals (28), while six SNPs were reported in the Han Chinese population (29).

In addition to these common variants identified through population-level studies, rare mutations have also been implicated in severe obesity cases. One such example is the *ADCY3*, which regulates *MC4R* trafficking. A homozygous frameshift mutation (c.3315del; p. Ile1106Serfs) in exon 21 of *ADCY3* was recently reported in severely obese Pakistani children (30). Besides, a different *ADCY3* variant, homozygous c.1102G>A (p. Asp368Asn), was identified through whole-exome sequencing in 10-year-old Turkish children (31), which has been associated with early-onset obesity, insulin resistance, and neurodevelopmental issues (31). Additional gene variants from the same pathway, such as semaphorin 3A-G (*SEMA3A-G*), plexinA1-4 (*PLXNA1-4*), and neuropilin 1-2 (*NRP1-2*), were identified in the adult obese population (32). In 2020, the FDA approved the first *MC4R* agonist, setmelanotide (RM-493), for the treatment of severe obesity (33, 34), marking a major milestone more than two decades after *MC4R* was first identified as a therapeutic target. This highlights the translational potential of genetic discoveries into clinical practice, as seen with the approval of setmelanotide for *MC4R*-related obesity. However, such pharmacogenomic advancements have largely been derived from studies conducted in Western populations, raising concerns about their relevance and applicability in other regions.

The Southeast Asian region comprises Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand, and Vietnam (35). It has experienced a significant rise in obesity prevalence, projected to double from 2010 to 2030, affecting up to 45 million individuals (36). Given the region's rich ethnic diversity, unique dietary patterns, and distinct genetic backgrounds, it remains unclear whether genetic risk factors and treatment responses observed in Western populations are applicable to Southeast Asians. This raises an important question: do population-specific genetic markers exist that better explain obesity risk and potentially guide personalised treatment strategies in this region?

Building on this need for region-specific genetic data, a GWAS meta-analysis performed on Singaporeans, Malays, and Asian Indians confirmed the association between the *FTO* and obesity (37). The study successfully replicated 13 loci previously identified in European cohorts and reported three novel SNPs (rs2287019, rs2241423, and rs516175) linked to increased BMI in these Asian populations. Interestingly, 16 loci found in European GWAS were absent in Southeast Asians, which could be attributed to genetic heterogeneity. These findings underscore the importance of tailoring genetic research to local populations.


Further supporting the relevance of *FTO* in Asian contexts, a meta-analysis of 26 studies concluded a significant association between *FTO* SNPs and obesity risk in the Chinese population (OR = 1.30; 95% CI: 1.19, 1.42;  $P < 0.001$ ) (38). Similarly, in Asian Indians, a minor A allele of the *FTO*, rs9939609, was associated with increased obesity risk (OR = 1.15; 95% CI: 1.08, 1.21,  $P = 2.14 \times 10^{-5}$ ) (39). In contrast to findings in other Asian populations, no association was reported between 31 variants of *FTO* SNPs and obesity traits in Malaysians (40). Similarly, although a meta-analysis from 39 studies revealed a significant association between rs1137101 *LEPR* and obesity under the homozygous model (GG vs AA: OR = 1.39; 95% CI: 1.12, 1.73,  $P = 0.003$  in Caucasians and Asians (23), this association was not observed in the multi-ethnic Malaysian populations (41, 42).

These inconsistencies across ethnic groups highlight the complexity of genetic predisposition to obesity, which may differ widely due to ancestry diversity, environmental interactions, and population sampling differences in Southeast Asia. Hence, this review aims to map the current landscape of genetic polymorphisms associated with obesity in the Southeast Asian population. By identifying established findings and highlighting knowledge gaps, we hope to support future research tailored to the region's unique genetic and environmental context.

## Methods

### Search Strategy

This systematic review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 and a systematic review without meta-analysis (SWiM) guidelines. The review has been registered under the International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42024575327). The protocol can be assessed through [https://www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=575327](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=575327). A combination of Medical Subject Headings (MeSH) terms was used for the search, including: 1) Adiposity; 2) Body Mass Index; 3) Obesity; 4) Overweight; 5) Gene Polymorphism; 6) Single Nucleotide Polymorphism; 7) SNPs; 8) Genome-Wide Association Studies; 9) GWAS; and 10) Southeast Asia. These terms were combined using Boolean operators (AND/OR) as follows: [(1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9) AND 10]. A total of 2,021 articles were retrieved from three electronic databases: Web of Science, PubMed, and Scopus. These articles were downloaded into EndNote 20.6 software, and 469 duplicate articles were removed. The titles and abstracts of the remaining studies were screened to select those relevant to gene polymorphism in the Southeast Asian population. The full texts of 55 studies were assessed for eligibility, and 25 were selected for review. The study retrieval and selection summary are presented in Figure 1 as a PRISMA flow chart.



**Figure 1.** The PRISMA flow chart summarises the study retrieval, screening, and selection procedure

### Selection Criteria

Full-text articles published in English within the past 15 years (2010–2024) were selected. The PECOS criteria for study inclusion and exclusion are detailed in Table 1. Only case-control, cross-sectional, and cohort studies were included; animal studies and clinical trials were excluded. The target population was Southeast Asians aged 18 to 70 years. Newborns, children, and individuals over 70 years old were excluded. Full texts of the studies were meticulously screened, and only those focusing on gene polymorphism related to obesity parameters were selected for data extraction.

### Data Extraction and Management

Data extraction was performed from 25 studies that passed the eligibility screening criteria. The following information was extracted

and tabulated in Table 2. The following information was extracted:

- i) Gene, chromosome location, SNPs, and allele
- ii) Country (population), study design, sample size, and sample characteristics (age and ethnicity)
- iii) Genotyping method, definitions of obesity based on different BMI thresholds, and overall findings
- iv) Odds ratio (95% CI), regression ( $\beta$ ) coefficient (95% CI), and *P*-value

Significant heterogeneity was identified during data extraction, including the study design, type of SNPs, BMI thresholds for obesity, and population types. Hence, a SWiM was carried out per the published guideline (43). The PRISMA 2020 checklist and SWiM reporting items are in the supplementary file. As per SWiM protocol, the populations, study design, and outcome were tabulated and illustrated via graphical presentation.

**Table 1.** PECOS criteria of the studies

Criteria	Inclusion	Exclusion
Population	Southeast Asia participants 19 to 69 years old All genders and ethnicities	<i>In vitro</i> cell model Animals < 18 years old > 70 years old
Exposure	Combination of genetic susceptibility (e.g. candidate genes, genome-wide association studies, polygenic risk scores, genetic risk scores, single nucleotide polymorphisms) and obesity risk parameters	Studies that did not include both exposures
Comparison	Non-obese participants	-
Outcome	Obesity risk factor (weight-related anthropometric measurements [BMI, weight, waist circumference, waist-to-hip ratio, body fat])	Studies that failed to report the desired outcome
Study design	Cohort, case-control, cross-sectional	Clinical trials, including randomised and non-randomised, animal studies

**Table 2.** Summary of study characteristics and main findings of the selected articles

Gene and chromosome location	SNPs and alleles	Country (reference) Study design and sample size	Genotyping method Obese definition	Sample characteristics Age (years) Ethnicity	Findings	Highest OR 95% CI P-value
G: FTO	rs1077128	Malaysia (40)	Sequenom	48.29 ± 9.89	rs17817288 was significantly associated with LDL-C	NR
L: 16q12.2	rs11643744	Cross-sectional	MassARRAY®	Malay		
	rs7186521	N = 587	iPLEX Platform			
	rs13334933	Obese	(MALDI-TOF)		No significant difference in genotype or allelic frequency for SNPs between obese and normal groups	
	rs16952517	n = 158	≥ 30.0 kg m <sup>2</sup>			
	rs6499643	Non-obese				
	rs4784323	n = 429				
	rs7206790					
	rs9939973					
	rs1421085					
	rs1558902					
	rs10852521					
	rs16952522					
	rs17817288					
	rs1121980					
	rs16945088					
	rs17817449					
	rs8050136					
	rs9935401					
	rs3751812					
	rs9939609					
	rs7190492					
	rs7204609					
	rs17218700					
	rs11642841					
	rs1861867					
	rs11075994					
	rs1421090					
	rs17818902					
	rs7191513					

(continued on next page)

**Table 2.** (continued)

Gene and chromosome location	SNPs and alleles	Country (reference) Study design and sample size	Genotyping method Obese definition	Sample characteristics Age (years) Ethnicity	Findings	Highest OR 95% CI P-value
G: <i>LEP</i> A19G L: 7q32.1	rs2167270	Malaysia (41) Cross-sectional N = 408	PCR-RFLP > 27 kg/m <sup>2</sup>	52.4 ± 13.7 Malay = 148 Chinese = 177 Indian = 83	Not all SNPs are associated with obesity among Malaysians	OR = NR
G: <i>LEP</i> G2548A L: 7q32.1	rs7799039	Obese n = 190				
G: <i>LEPR</i> K109R L: 1p31.3	rs1137100	Non-obese n = 218				
G: <i>LEPR</i> Q223R L: 1p31.3	rs1137101					
G: <i>LEP</i> G2548A L: 7q32.1	rs7799039	Malaysia (42) Cross-sectional N = 185	PCR-TaqMan > 29.9 kg/m <sup>2</sup>	20.84 ± 2.2 Malay = 61 Chinese = 45 Indian = 56 Others = 23	No significant association was found between ethnic groups with <i>LEP</i> , G2548A and <i>LEPR</i> , Q223A	LEPR, Q223R of AA genotype association with obesity OR = 2.50 CI = 0.11, 59.9 P = 0.50
G: <i>LEPR</i> Q223R L: 1p31.3	rs1137101	Obese n = 95 Non-obese n = 87			<i>LEPR</i> polymorphism showed no association with plasma leptin Overweight and obese participants were in stage I of leptin resistance	
G: <i>ADRA2A</i> L: 10q25.2	rs553668	Malaysia (44) Cross-sectional N = 214	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	26.27 ± 11.93 Malay = 45 Chinese = 116 Indian = 53	People with both <i>ADRA2A</i> , rs553668 GG and <i>ACE</i> I/D II significantly has lowest WHR, could be due to gene-gene interaction	<i>ACE</i> associated with central adiposity OR = 2.02 CI = 0.87, 4.70 P = 0.10
G: <i>ACE</i> L: 17q23.3	rs4646994	Obese n = 142 Non-obese n = 72				
G: <i>ADRB2</i> L: 5q32	rs1042714	Malaysia (45) Cross-sectional N = 672 Obese n = 17 Non-obese n = 500	PCR-Taqman SNP > 90 cm for men > 80 cm for women	48.22 ± 10.05 Malay	rs1042714 was significantly associated with log-transformed HDL-C, DBP, and TG No association found towards BMI and obesity	OR = NR
G: <i>DRD2</i> Taq1A L: 11q23.2	rs1800497	Malaysia (46) Case-control N = 394 Obese n = 67 Non-obese n = 327	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	52.4 ± 13.7 Chinese = 308 Indian = 86	<i>DRD2</i> , Taq1 SNPs were not associated with adiposity and obesity, but have influenced eating behaviour	<i>DRD2</i> , Taq1 A genotype association with WHR OR = 1.19 CI = 0.57, 2.47 P = 0.64
G: <i>DRD2</i> L: 11q23.2	rs1079597					
G: <i>DRD2</i> Taq1D L: 11q23.2	rs1800498					
G: <i>ADIPOQ</i> L: 3q27.3	rs17366568 rs3774261	Malaysia (47) Cross sectional N = 574 Obese n = 150 Non-obese n = 424	Sequenom MassARRAY TaqMan PCR ≥ 30 kg/m <sup>2</sup>	45.89 ± 6.34 Malay	<i>ADIPOQ</i> rs17366568 significantly associated with obesity, while rs3774261 not significantly associated Genotypes AG and AA of rs17366568 significantly higher in obese group	A allele in obese group OR = 2.15 CI = 1.13, 4.09 P = 0.024

(continued on next page)



Table 2. (continued)

Gene and chromosome location	SNPs and alleles	Country (reference) Study design and sample size	Genotyping method Obese definition	Sample characteristics Age (years) Ethnicity	Findings	Highest OR 95% CI P-value
G: <i>ACE</i> L: 17q23.3	Insertion/ deletion (I/D)	Malaysia (48) Cross sectional N = 219 Obese n = 94 Non-obese n = 123	PCR-RFLP ≥ 30 kg/m <sup>2</sup>	35.22 ± 10.10 Malay	<i>ACE</i> gene I/D polymorphism is not associated with obesity and obesity-related phenotypes	<i>ACE</i> ID genotype association with obesity OR = 1.32 CI = 0.75, 2.34 P = 0.335
G: <i>FTO</i> L: 16q12.2	Rs9930506	Malaysia (49) Cross-sectional N = 178 Obese n = 79 Non-obese n = 99	PCR-RFLP ≥ 27.5 kg/m <sup>2</sup>	41.7 ± 0.9 Chinese = 42 Malay = 86 Indian = 50	rs9930506 (G) not associated with obesity in dominant model but associated with codominant model	rs9930506, GG, associated with obesity in codominant model OR = 2.87 CI = 1.14, 7.19 P = 0.02
G: <i>IL1RA</i> intron 2 L: 2q14.1	NR	Malaysia (50) Case-control N = 315 Obese n = 54 Non-obese n = 261	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	20.6 Malay = 23 Chinese = 251 Indian = 41	Individuals with <i>IL1RA</i> I/II genotype or allele II showed higher risk of having adiposity	<i>IL1RA</i> , I/II OR = 12.21 CI = 2.54, 58.79 P = 0.002
G: <i>IL4</i> L: 5q31.1	NR					
G: <i>LEP</i> G2548A L: 7q32.1	rs7799039	Malaysia (51) Case-control N = 249 Obese n = 148 Non-obese n = 101	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	Age: NR Malay	No significant single association between SNPs and BMI and obesity Haplotype AAG of G2548A, H1328080, and A19G reported to have significant association with obesity	AAG haplotype association with obesity OR = 8.89 CI = 1.59, 49.78 P = 0.002
G: <i>LEP</i> A19G L: 7q32.1	rs2167270					
G: Leptin H1328080 L: chr7 128238282	rs12535747					
G: <i>UCP1</i> L: 4q31.1	rs1800592 (A/G)	Malaysia (52) Case-control N = 447 Obese n = 111 Non-obese n = 336	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	24.66 ± 6.90 Malay = 46 Chinese = 339 Indian = 62	Lack of association between single <i>UCP1</i> /3 and obesity Combination of <i>UCP1</i> A allele and <i>UCP3</i> C allele associated with WHR Combination of <i>UCP1</i> AA and <i>UCP3</i> CC genotypes showed elevated BMI	T allele had significantly less risk of obesity in Chinese OR = 5.69 CI = 5.48, 1.00 P = 5.04
G: <i>UCP3</i> L: 11q13.4	rs1800849 (T/C)					
G: <i>UCP2</i> L: 11q13.4	Insertion/ deletion (I/D)	Malaysia (53) Case-control N = 926 Obese n = 265 Non-obese n = 661	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	33.96 ± 8.51 Malay = 102 Chinese = 672 Indian = 152	<i>UCP2</i> 45-bp I/D polymorphism is associated with overall adiposity in Malaysian women	ID genotype associated with overall adiposity OR = 2.02 CI = 1.18, 3.45 P = 0.01

(continued on next page)

**Table 2.** (continued)

Gene and chromosome location	SNPs and alleles	Country (reference) Study design and sample size	Genotyping method Obese definition	Sample characteristics Age (years) Ethnicity	Findings	Highest OR 95% CI P-value
G: <i>PPARα</i> L162V L: 22q13.31	NR	Malaysia (54) Cross-sectional N = 307	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	53.3 ± 14.2 Malay = 97 Chinese = 85 Indian = 55	No significant association of SNPs with obesity and metabolic syndrome  <i>PPARα</i> , V162 allele carriers associate with high plasma IL-6 level	<i>PPARα</i> , L162V association with obesity and metabolic syndrome OR = 1.732 CI = 1.34, 8.77 P = 0.50
G: <i>PPARγ2</i> C161T L: 6p21.31	NR	Obese n = 18 Non-obese n = 127				
G: <i>PPARδ</i> T294C L: 3p25.2	NR					
G: <i>FTO</i> L:16q12.2	rs9939609	Indonesia (55) Case-control N = 80 Obese n = 38 Non-obese n = 40	ARMS PCR ≥ 25 kg/m <sup>2</sup>	32 Indonesian	Participants with the AT/AA genotypes reported to have 3.72 greater risk of obesity and 5.98 times higher risk for dietary fat intake	AT/AA genotypes associated with obesity OR = 3.72 CI = 1.19, 11.64 P = 0.009
G: <i>FTO</i> L:16q12.2	rs1421085	Indonesia (56) Case-control N = 71 Obese n = 35 Non-obese n = 36	ARMS PCR ≥ 25 kg/m <sup>2</sup>	32 (27.5 ± 36.8) Indonesian	CC genotype reported to show higher BMI TC/CC genotypes had higher monounsaturated and saturated fatty acid intakes than TT genotype	CC genotype has high BMI in recessive model Coef = 12.38 CI = 5.3, 19.46 P ≤ 0.001
G: <i>UCP2</i> L: 11q13.4	rs659366	Indonesia, Yogyakarta (57) Prospective cohort study N = 323	PCR-RFLP NR	42.8 ± 9.7 Indonesian	GG genotype showed more weight gain and influenced energy intake <i>UCP2</i> does not associated with adiposity in 2 2-year follow-up	GG genotype positively correlated with body weight β = 0.232 P = 0.016
G: <i>GHRL</i> L: 3p25.3	Leu72Met	Indonesia (58) Case-control study N = 198 Obese n = 100 Non-obese n = 98	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	22.06 ± 4.08 Javanese	CA mutant genotype was found in 42.2% of obese group Leu72Met polymorphism increases the risk of obesity	Genotype AA+CA in obese OR = 4.96 CI = 2.43, 10.12 P ≤ 0.001
G: <i>FTO</i> L:16q12.2	rs9939609 rs1421085	Indonesia (59) Cross-sectional study N = 612 Normal n = 270 Overweight n = 218 Obese n = 121	ARMS PCR ≥ 25 kg/m <sup>2</sup>	46.6 ± 14.6 Balinese	The minor AA of rs9939609 and CC of rs1421085 increased BMI and were associated with obesity	rs1421085 is associated with high BMI OR = 3.22 CI = NR P ≤ 0.001
G: <i>LEPR</i> L: 1p31.3	rs1137100 rs1137101	Indonesia (60) Cross-sectional study N = 110 Obese n = 55 Non-obese n = 55	PCR-RFLP NR	20.7 ± 3.7 Indonesian	rs1137100 (K109R) and rs1137101 (Q223R) correlated with obesity and leptin level	LEPR, rs1137100 (K109R) genotype association with body weight OR = NR P = 0.000

(continued on next page)



Table 2. (continued)

Gene and chromosome location	SNPs and alleles	Country (reference) Study design and sample size	Genotyping method Obese definition	Sample characteristics Age (years) Ethnicity	Findings	Highest OR 95% CI P-value
G: <i>RETN</i> L: 19p13.2	rs3745368	Indonesia (61) Case-control N = 122 Obese n = 61 Non-obese n = 61	PCR-RFLP ≥ 27 kg/m <sup>2</sup>	22 Javanese	No association found between genotypes and alleles and obesity parameters and resistin levels	<i>RETN</i> , GG phenotype association with obesity OR = 2.07 CI = 0.36, 11.74 P = 0.680
G: <i>IL-6</i> L: 7p15.3	-174 G>C	Indonesia-western ethnic (62) Case-control N = 178 Obese n = 89 Non-obese n = 89	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	22.1 ± 4.1 Indonesian	CC genotype had higher plasma CRP and lower <i>IL-6</i> levels than the GC and GG genotypes in obese group Obese population has more CC genotype than control	CC genotype associated with obese and control subjects OR = 7.39 CI = 2.26, 25.71 P = 0.0005
G: <i>UCP2</i> L: 11q13.4	rs660339	Indonesia (63) Case-control N = 200 Obese n = 100 Non-obese n = 100	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	22.35 ± 4.81 Javanese	I/D genotypes were associated with obesity after gender stratification	Frequency of 45 bp II genotype in obese and control groups OR = 2.33 CI = 0.58, 9.40 P = 0.22
G: <i>UCP2</i> G(-866)A L: 11q13.4	rs659366	Indonesia (64) Cross-sectional N = 603	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	49 ± 13 Balinese	No association between both <i>UCP</i> polymorphism and obesity traits	OR = NR
G: <i>UCP2</i> Ala55Val (C>T) L: 11q13.4	rs660339	Obese n = 217 Non-obese n = 386			Rural people with A/A genotype of G(-866)A has high BMI	
G: <i>UCP1</i> L: 4q31.1	rs1800592	Vietnam, Hai Duong (65) Case-control N = 140	PCR-RFLP ≥ 25 kg/m <sup>2</sup>	55.6 ± 3.8, Postmenopausal women Vietnamese	<i>VDR</i> polymorphisms, Basim and ApaI associated with overweight and obesity	<i>VDR</i> ApaI association with overweight and obese population OR = 3.00 CI = 1.08, 8.36 P = 0.03
G: <i>ADRA2B</i> L: 2q11.2	rs4994				<i>VDR</i> and <i>ESR1</i> interaction reported to have effect on adiposity	
G: <i>ESR1</i> L: 6q25.1 q25.2	rs2234693 rs9340799					
G: <i>VDR</i> L: 12q13.11	rs2228570 rs1544410 rs7975232 rs731236					

I/D = insertion/deletion; OR = odds ratio; CI = confidence interval; NR = not reported; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; SNP = single nucleotide polymorphism; WHR = waist-to-hip ratio; HDL-C = high-density lipoprotein cholesterol; DBP = diastolic blood pressure; TG = triglycerides; BMI = body mass index; ARMS = amplification refractory mutation system

### Risk of Bias Grading Classification

The quality of the selected articles was assessed using the Newcastle-Ottawa Scale (NOS), a tool specifically designed for evaluating non-randomised studies. According to Wells et al. (66), the NOS has four main criteria for assessing the quality of studies screened for inclusion in meta-analyses: the selection of study groups, the comparability of study groups, the methods used and non-response rates of the participants for exposure assessment. The scoring system is as follows:

- i) High quality: Studies that score between 7 and 9 stars
- ii) Fair quality: Studies that score between 4 and 6 stars
- iii) Low quality: Studies that score between 1 and 3 stars


Two investigators were independently assigned to evaluate the quality of the identified studies based on the NOS scale.

## Results


### General Characteristics of the Included Studies

Twenty-five studies published between 2010 and 2024 were selected through a systematic search. No studies were published in 2010, 2013, 2023, or 2024. The highest number of publications was in 2018, with four articles (16% of the total). Regarding the geographical distribution of research, 14 studies focused on Malaysians (40–42, 44–54), followed by 10 studies on Indonesians (55–64) and one study on Vietnamese (65). The combined population across the 25 studies consisted of 8,312 participants representing five ethnic groups: Malay, Chinese, Indian, Javanese, and Balinese. Malay participants comprised the largest group, comprising 35% of the total, with 2,909 individuals. This was followed by Chinese participants, who comprised approximately 24.4% of the total with 2,035 individuals, and Balinese participants, who represented 14.6% with 1,215 individuals. Notably, about 12% of participants across seven studies did not have their ethnicity disclosed, with these studies primarily conducted in Indonesia and Vietnam. A summary of the distribution of studies by year, country, and ethnicity is illustrated in Figure 2.


(A) Distribution of publications by years



(B) Distribution by country




(C) Distribution by ethnicities



**Figure 2.** The distribution of the 25 selected studies by years, their respective populations, and ethnicities

This review included 25 studies, comprising 12 case-control studies, 12 cross-sectional studies, and one cohort study. Regarding genotyping methods, Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was the most used, featured in 18 studies, accounting for 72% of the total. Amplification refractory mutation system (ARMS) PCR was used in three studies, quantitative PCR (qPCR) was used in two studies, and Sequenom MassArray® was used in two studies. Figure 3 illustrates the summary of study designs and genotyping methods.



**Figure 3.** The distribution of genotyping methods and study designs among the 25 studies

### Risk of Bias Evaluation

We evaluated the quality of the selected studies using the NOS. Of the 25 studies assessed, 18 were categorised as high quality, six as fair quality, and one as low quality. Sample size calculations were reported in the minority of studies ( $n = 9$ ; 36%). One study (64) was rated as low quality, receiving only two stars due to the absence of data on the frequency of obesity among the obese and non-obese groups. The authors accumulated medical history through questionnaires from the participants, which showed ascertainment of exposure. The participants were postmenopausal women, who were not an accurate representation of the obese Vietnamese population. Additionally, six studies (44, 46, 50, 52, 53, 63) recruited participants from university students and staff, limiting the generalisability of the results to the broader population. Students' unique lifestyles and environments do not reflect those of the general working adult population. Furthermore, due to the pervasive use of the convenience sampling method, several studies oversampled Chinese participants (44, 46, 50, 52, 53), which does not reflect the actual population's demographic composition. Similarly, other studies focused exclusively on the Malay ethnicity (40, 45, 47, 48, 51), limiting the generalizability of their findings to the overall Malaysian population. Four studies (49, 55, 56, 65) relied on self-reported medical histories, which may introduce recall bias. One study (62) utilised BMI values on a continuous scale as the outcome measure, which is insufficient for predicting the associations between the investigated SNPs and the obesity category. Meanwhile, another study (51) did

not report the anthropometric measurements of the participants, further limiting the study's conclusions. The summary of the risk of bias assessment is presented in Tables 3, 4 and 5.

Due to the profound heterogeneity in the inter-study methodological quality, we did not proceed with meta-analysing the study results. Therefore, we opted for a narrative systematic review to synthesise the results from different studies.

### Discussion

The current review highlights several Southeast Asian studies investigating the association between obesity-related gene polymorphisms and obesity risk. This region offers a unique opportunity to understand how genetic variation, interacting with diverse environmental exposures and ethnic backgrounds, contributes to the complexity of obesity. Among the genes most extensively studied in the selected literature are *LEP* and *LEPR* (41, 42, 51, 60). Leptin, encoded by the *LEP*, plays a key role in regulating appetite, body weight, and fat metabolism (67). It is secreted primarily by white adipose tissue and acts by binding to its receptor, *LEPR*, in hypothalamic neurons, where it suppresses food intake and promotes energy expenditure (68, 69).

Several studies in Malaysia and Indonesia have evaluated the common *LEP* and *LEPR* variants, though findings have been inconsistent. For example, in a study of 408 Malaysians, Fan and Say (41) reported no significant association between *LEP* SNPs rs2167270 and rs7799039, as well as *LEPR* SNPs rs1137100 and rs1137101 with obesity risk. However, these variants were significantly associated with obesity in the Chinese populations. The lack of significant findings in the Indian subgroup was likely influenced by a smaller sample size, where the statistical power ranged from 57% to 63% (41). Similarly, Wan Rohani et al. (51) found no significant association between the *LEP* variants rs2167270 and rs7799039 and obesity in a study involving 249 Malays in Malaysia. Nevertheless, the same study reported that the AAG haplotype formed by three *LEP* SNPs, rs7799039, rs2167270, and rs4731426, was significantly associated with obesity, with an odds ratio (OR) of 8.89 (95% CI: 1.59, 49.78) (51). In contrast, another study involving 185 multi-ethnic Malaysians found no association between

**Table 3.** The Newcastle-Ottawa Scale for the quality assessment of the selected case-control studies

Author	Selection				Comparability		Exposure		Total score
	Is the case definition adequate?	Representativeness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-response rate	
Apalasamy et al. (45)	*		*	*	*	*	*	*	7
Wan Rohani et al. (51)	*		*	*	*	*	*	*	7
Lee et al. (52)	*		*	*	*		*		5
Say et al. (53)	*		*	*	*		*	*	6
Chia et al. (54)	*		*	*	*	*	*	*	7
Al-Jawadi et al. (56)	*	*	*	*	*		*	*	8
Muhammad et al. (57)	*	*	*	*	*		*	*	7
Priliani et al. (59)	*	*	*	*	*	*	*	*	8
Pramudji et al. (62)	*	*	*	*	*	*	*	*	8
Surniyantoro et al. (63)	*	*	*	*	*	*	*	*	8
Oktavianthi et al. (64)	*		*	*	*	*	*	*	7
Binh et al. (65)							*	*	2

**Table 4.** The Newcastle-Ottawa Scale for the quality assessment of the selected cross-sectional studies

Author	Selection				Comparability	Outcome		Total
	Representatives of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor)	Comparability of studies on the basis of the design or analysis	Assessment of the outcome	Statistical test	
Fan et al. (41)	*	*	*	*	*	*	*	7
Mohanraj et al. (42)	*	*	*	*	*	*	*	7
Campbell et al. (43)	*	*	*	*	*	*	*	7
Apalasamy et al. (45)		*	*	*	*	*	*	6
Lek et al. (46)	*	*	*	*	*	*	*	7
Apidi et al. (48)		*	*	*	*	*	*	6
Mitra et al. (49)	*	*	*	*	*	*	*	7
Kok et al. (50)	*		*		*	*	*	5
Daya et al. (55)	*	*	*	*	*	*	*	7
Hastuti et al. (60)	*	*	*	*	*	*	*	7
Utami et al. (61)	*	*	*	*	*	*	*	7

**Table 5.** The Newcastle-Ottawa Scale for the quality assessment of the selected cohort study

Author	Selection				Comparability		Outcome		Total
	Representatives of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of the cohort on the basis of the design or analysis	Assessment of the outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	
Martantiningtyas et al. (58)	*	*	*	*	*	*	*	*	8

BMI and *LEP* rs7799039 ( $P = 0.117$ ) and *LEPR* rs1137101 ( $P = 0.469$ ), nor between leptin levels and these SNPs (*LEP* rs7799039:  $P = 0.196$ ; *LEPR* Q223A:  $P = 0.453$ ) (42). Conversely, a cross-sectional study from Indonesia found a positive association between rs1137100 and rs1137101 *LEPR* with both obesity and leptin levels (60). Specifically, obese individuals with the RR genotype of rs1137100 in the *LEPR* had leptin levels that were 99% higher, with an average BMI of 36.10, compared to controls with a BMI of 22.04. Additionally, obese individuals with the KK+KR genotype had leptin levels that were 28.3% higher, with an average BMI of 33.86, compared to controls with a BMI of 22.17 (60).

Unlike these positive associations observed in Indonesia and other populations, most studies in Malaysia have reported no significant links between *LEP* variants and obesity. This contradicts the findings from Finnish (70), Caucasians (71, 72), Saudi Arabian (73), and European populations (74), where *LEP* polymorphisms were associated with obesity traits. These inconsistencies may be attributed to small sample sizes, varying study designs, and the use of non-random purposive sampling, which limits the generalizability of findings (41, 51). Additionally, genetic factors such as differences in linkage disequilibrium patterns, allele frequencies, and population structure across ethnic groups may contribute to the divergent associations observed in obesity-related SNPs (75, 76).

Supporting this complexity, a meta-analysis of nine studies involving 2,988 participants concluded that the rs7799039

*LEP* polymorphism is not generally associated with the development of obesity. However, a significant association was observed in specific populations, including a small South American ( $n = 788$ ) (77) and in the Tunisian ( $n = 329$ ) population (78), where rs7799039 was associated with increased obesity risk, suggesting the influence of population-specific genetic factors. Similarly, *LEPR* polymorphisms have shown ethnic variation. In Caucasian populations, rs1137100 showed a significant association in both BMI and fat mass ( $P = 0.02$  and  $P = 0.05$ ), while rs1137101 was also significantly linked to BMI ( $P = 0.005$  and  $P = 0.03$ ) (79).

In addition, *FTO* variants, first identified as being positively associated with obesity in European populations (80), have been studied across four Asian ethnicities: Balinese Indonesians, Malays, Chinese, and Indians in Malaysia (40, 49, 55, 56, 59). A study conducted in Jakarta, although not specifying participants' ethnicity, found that those with the AT/AA genotypes of rs9939609 *FTO* had a 3.72-fold higher risk of obesity (55). Similarly, the minor AA genotype of rs9939609 *FTO* increased BMI by 1.25 kg/m<sup>2</sup> ( $P = 0.012$ ), while the CC genotype of rs1421085 increased by 1.12 kg/m<sup>2</sup> ( $P = 0.022$ ), particularly in females (59). The minor allele frequency (MAF) of this study was 0.19, consistent with findings from studies conducted among multi-ethnic Malaysians (81) and Minangkabau Indonesians (82). The study involving 275 Minangkabau Indonesians reported that the AA genotype of rs9939609 *FTO* has significantly higher body fat, weight, waist-hip ratio, and BMI of 27.39 (SD 4.69) compared to TT, which has a BMI of 23.96



(SD 4.51) and TA of about 24.56 (SD 4.8) (82). Additionally, the GG genotype of another rs9930506 *FTO* was found to be associated with obesity in the Malaysian population under a codominant model (49). The CC genotype of the rs1421085 variant in Indonesians was linked to a higher BMI of 12.58 kg/m<sup>2</sup> ( $P = 0.001$ ) in codominant and 12.38 kg/m<sup>2</sup> ( $P < 0.001$ ) in the recessive model compared with those without this variant, indicating a recessive trait (56). The MAF was 22%, lower than that observed in the Balinese population (59). However, a study involving 587 Malays failed to find an association between 31 *FTO* SNPs genotypes and allelic frequencies with obesity, except for rs17817288, which was significantly associated with LDL-C (40). Moreover, a GWAS study conducted among Singaporean Chinese also found no association between *FTO* variants and BMI (83). This highlights the possibility that ethnic-specific gene-environment interactions or other modifying loci may modulate the effect of *FTO* variants.

*UCP*, primarily located in mitochondria, plays a key role in regulating thermogenesis and energy expenditure while also offering protection against oxidative stress (84). The A/G genotype of rs1800592 *UCP* was the initial SNP established by Canadian scientists in 1994 to be associated with high BMI in individuals with a family history of obesity. In Southeast Asia, *UCP* polymorphisms were studied in three different populations, including Malaysia, Indonesia, and Vietnam (52, 53, 57, 63, 65). The combination of the rs1800592 *UCP1* AA genotype and the rs1800849 *UCP3* CC genotype has been notably associated with a higher waist-hip ratio (WHR) of 0.85 (SD 0.10) and a BMI of 26.17 (SD 5.27) compared to other genotype combinations such as AA/TT, GG/CC, and GG/TT, which are associated with lower BMIs of 22.11 (SD 3.01), 22.05 (SD 3.77), and 22.38 (SD 4.47), respectively, in the Malaysian Chinese population (52). Interestingly, the presence of the T allele of *UCP3* in the Chinese population is linked to a reduced risk of obesity, as carriers of the T allele exhibit a 30% lower risk of central obesity and a 2.5% lower WHR compared to those with the C allele (52). This suggests a potential protective effect of the T allele against obesity. Moreover, while *UCP1* alone is not significantly associated with WHR, its combination with *UCP3* appears to have a synergistic effect, significantly influencing obesity and adiposity. Meanwhile, unlike

Malaysians, the G allele of rs1800592 *UCP1* was susceptible to weight gain compared to the A allele in the Finnish population (85). A similarly significant association was found for the minor G allele with BMI (OR: 1.52, CI: 1.10, 2.08,  $P = 0.009$ ) in the Saudi Arabian population (86) and associated to fat mass ( $P = 0.002$ ) and muscle mass ( $P = 0.019$ ) in Mexican adults (87).

Furthermore, Say et al. (53) reported a significant association between the *UCP2* gene polymorphism and adiposity in Malaysian women. In the Chinese population, the MAF of *UCP2* was 0.12, consistent with findings in other Chinese cohorts (88). Among Indians, the MAF was higher, at 0.21, similar to data from southern Indians of Tamil Nadu, India (89). This difference may be attributed to the historical migration patterns and ancestral connections between Malaysian Indians and Chinese and their mainland counterparts. In contrast, the TT genotype and T allele of *UCP2* carry less risk of obesity compared to the C allele, as the OR CI of TT was 0.4 (95% CI: 0.13, 1.20), while the T allele was 0.55 (95% CI: 0.32, 0.95) in male Indonesian Javanese (63). Besides, an Indonesian Nutrigenetic Cohort reported that individuals with the GG genotype for rs659366 *UCP2* are associated with high energy intake, body fat, and weight (57), and the AA genotype has been positively associated with higher BMI in the rural Balinese population (64). Besides, a pairwise gene-gene interaction analysis of vitamin D receptor (*VDR* ApaI) and *UCP2* demonstrated a significant interaction ( $P = 0.003$ ) and 69% predictive accuracy for overweight and obesity in postmenopausal Vietnamese women (65).

The *ADR2A* was first noted to have a crucial role in regulating insulin secretion and lipolysis (OR = 1.62; 95% CI: 1.06, 2.49;  $P = 0.026$ ) in Swedish obese individuals without T2DM (90), with a stronger association with obesity in Swedish women with T2DM (OR = 7.61; 95% CI: 1.70, 34.17;  $P = 0.008$ ) (91). In Malaysians, a gene-gene interaction between rs553668 *ADR2A* and the angiotensin-converting enzyme rs4646994 *ACE* polymorphisms was associated with lower central adiposity (44, 53). However, in a separate study in the Malay population, no significant association was found between the *ACE* variant and obesity parameters (48).

Based on the findings from these studies, several limitations and challenges were found that prevent the definitive ascertainment of SNPs associated with obesity and the generalisability of the results to the wider Southeast Asian



population. First, there is a significant gap in replicating the results consistently across different populations and ethnic groups due to population-specific genetic factors. Second, the small sample sizes employed in many studies have also limited the study power to detect significant associations between SNPs of smaller effect sizes (e.g. smaller ORs) and obesity. Thus, inter-country collaboration within the Southeast Asian region may be leveraged to increase the number of study participants and improve study power. Besides, Southeast Asia has experienced rapid urbanisation and economic growth in recent decades, which has led to substantial changes in diet and physical activity patterns (36). These environmental shifts could exacerbate the impacts of genetic factors on obesity through gene-environment interaction, particularly among individuals carrying high-risk alleles (92). Furthermore, as reflected in Table 2, only three countries, Malaysia, Indonesia, and Vietnam, have conducted genetic association studies on obesity, highlighting a significant geographical research gap within the Southeast Asian region. This limited representation restricts the ability to generalise findings across the diverse ethnic and genetic backgrounds present in Southeast Asia.

## Conclusion

In conclusion, the reviews highlight the complex and multifaceted nature of obesity, particularly in the context of gene polymorphisms within Southeast Asian populations. The *LEP* and *UCP* polymorphisms are among the most studied in Southeast Asian populations. The *UCP* I/D polymorphism has been significantly associated with overall adiposity in Malaysian women, while in the Indonesian cohort, the GG genotype of *UCP2*, particularly the rs659366 variant, was linked to weight gain. On the other hand, *LEP* variants did not show a significant association with obesity in Malaysians. Similarly, the *FTO* shows population-specific effects. The rs9939609 variant was associated with obesity in Indonesians in two studies, and the rs1421085 variant was linked to a higher BMI. However, *FTO* variants were not significant determinants of obesity in the Malaysian population. These findings emphasise the potential of genetic

polymorphisms to serve as population-specific biomarkers for obesity, underlining the importance of precision-based approaches in prevention and management.

Moreover, the findings underscore the importance of considering the genetic diversity and environmental factors contributing to obesity and the challenges in replicating genetic associations across different ethnic groups. Future research should prioritise large-scale, multi-ethnic genomic studies to identify robust and reproducible biomarkers. Such efforts can inform targeted public health strategies and early interventions. Cross-border collaboration, particularly among developing nations, could enhance the exploration of population-specific genetic factors related to obesity. Ultimately, these initiatives could facilitate the development of biomarker-driven risk assessments, screening tools, and personalised interventions tailored to the unique genetic and environmental context of Southeast Asia.

## Acknowledgements

We thank the UKM Medical Molecular Biology Institute (UMBI), the Malaysian Cohort staff members and research assistants for their technical assistance in data collection. We also gratefully acknowledge the voluntary participation of all study participants.

## Ethics of Study

This study was reviewed and approved by the Institutional Review and Ethics Committee of Universiti Kebangsaan Malaysia (JEP-2024-113). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committees and with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from all participants prior to study participation.

## Conflict of Interest

None.

## Funds

We would like to acknowledge Universiti Kebangsaan Malaysia for their research grant (Dana Impak Perdana 2.0 [DIP-2023-025]. The funder did not participate in the preparation of the manuscript or influence its content or publication decision.

## Authors' Contributions

Conception and design: NA, UV, MIAJ, ARAJ  
Analysis and interpretation of the data: NA, UV, MIAJ

Drafting of the article: NA, UV

Critical revision of the article for important intellectual content: NA, UV, MIAJ, ARAJ, CSF, NAAM

Final approval of the article: NA, UV, MIAJ, ARAJ, CSF, NAAM

Provision of study materials or patients: NA, ARAJ

Statistical expertise: NA, MIAJ

Obtaining of funding: NA

## Correspondence

Dr. Noraidatulakma Abdullah  
PhD Medical Genetics (UoN), MSc Public Health (Epidemiology and Statistics) (UKM), BSc (Hons) Genetics (UKM)  
UKM Medical Molecular Biology Institute (UMBI),  
Jalan Yaacob Latiff,  
Bandar Tun Razak, 56000 Cheras,  
Kuala Lumpur, Malaysia  
Tel: +603-9145 9059  
E-mail: noraidatulakma.abdullah@ppukm.ukm.edu.my

## References

4. World Health Organization. Obesity and overweight [Internet]. Geneva: World Health Organization; 2024 [Retrieved 2024 Sep 22]. Available at: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
5. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. *Nat Rev Genet*. 2022;**23**(2):120–133. <https://doi.org/10.1038/s41576-021-00414-z>
6. Han JC, Rasmussen MC, Forte AR, Schrage SB, Zafar SK, Haqq AM. Management of monogenic and syndromic obesity. *Gastroenterol Clin North Am*. 2023;**52**(4):733–750. <https://doi.org/10.1016/j.gtc.2023.08.005>
7. Vourdoumpa A, Paltoglou G, Charmandari E. The genetic basis of childhood obesity: a systematic review. *Nutrients*. 2023;**15**(6):1416. <https://doi.org/10.3390/nu15061416>
8. Winer DA, Luck H, Tsai S, Winer S. The intestinal immune system in obesity and insulin resistance. *Cell Metab*. 2016;**23**(3):413–426. <https://doi.org/10.1016/j.cmet.2016.01.003>
9. Friedman JM. Leptin and the endocrine control of energy balance. *Nat Metab*. 2019;**1**(8):754–764. <https://doi.org/10.1038/s42255-019-0095-y>
10. Yeo GSH, Chao DHM, Siebert AM, Koerperich ZM, Ericson MD, Simonds SE, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. *Mol Metab*. 2021;**48**:101206. <https://doi.org/10.1016/j.molmet.2021.101206>
11. Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. *J Endocrinol*. 2019;**241**(1):R1–R33. <https://doi.org/10.1530/joe-18-0596>
12. Liu J, Lai F, Hou Y, Zheng R. Leptin signaling and leptin resistance. *Med Rev (2021)*. 2022;**2**(4):363–384. <https://doi.org/10.1515/mr-2022-0017>
13. Faccioli N, Poitou C, Clément K, Dubern B. Current treatments for patients with genetic obesity. *J Clin Res Pediatr Endocrinol*. 2023;**15**(2):108–119. <https://doi.org/10.4274/jcrpe.galenos.2023.2023-3-2>
14. Harbuzariu A, Oprea-Ilie GM, Gonzalez-Perez RR. The role of notch signaling and leptin-notch crosstalk in pancreatic cancer. *Medicines (Basel)*. 2018;**5**(3):68. <https://doi.org/10.3390/medicines5030068>
15. Jin X, Qiu T, Li L, Yu R, Chen X, Li C, et al. Pathophysiology of obesity and its associated diseases. *Acta Pharm Sin B*. 2023;**13**(6):2403–2424. <https://doi.org/10.1016/j.apsb.2023.01.012>
16. Kassouf T, Sumara G. Impact of conventional and atypical MAPKs on the development of metabolic diseases. *Biomolecules*. 2020;**10**(9):1256. <https://doi.org/10.3390/biom10091256>

17. Yarıbeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. *Oxid Med Cell Longev*. 2020;**2020**:8609213. <https://doi.org/10.1155/2020/8609213>
18. Bashan N, Dorfman K, Tarnowski T, Harman-Boehm I, Liberty IF, Blüher M, et al. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. *Endocrinology*. 2007;**148**(6):2955–2962. <https://doi.org/10.1210/en.2006-1369>
19. Mahmoud R, Kimonis V, Butler MG. Genetics of obesity in humans: a clinical review. *Int J Mol Sci*. 2022;**23**(19):11005. <https://doi.org/10.3390/ijms231911005>
20. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet*. 2007;**3**(7):e115. <https://doi.org/10.1371/journal.pgen.0030115>
21. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science*. 2007;**316**(5826):889–894. <https://doi.org/10.1126/science.1141634>
22. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, et al. The human obesity gene map: the 2005 update. *Obesity (Silver Spring)*. 2006;**14**(4):529–644. <https://doi.org/10.1038/oby.2006.71>
23. Kurokawa N, Young EH, Oka Y, Satoh H, Wareham NJ, Sandhu MS, et al. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44,833 individuals. *Int J Obes (Lond)*. 2008;**32**(8):1240–1249. <https://doi.org/10.1038/ijo.2008.90>
24. Wang D, Ma J, Zhang S, Hinney A, Hebebrand J, Wang Y, et al. Association of the MC4R V103I polymorphism with obesity: a Chinese case-control study and meta-analysis in 55,195 individuals. *Obesity (Silver Spring)*. 2010;**18**(3):573–579. <https://doi.org/10.1038/oby.2009.268>
25. Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W, et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. *Eur J Hum Genet*. 2009;**17**(8):1050–1055. <https://doi.org/10.1038/ejhg.2008.272>
26. Supti DA, Akter F, Rahman MI, Munim MA, Tonmoy MIQ, Tarin RJ, et al. Meta-analysis investigating the impact of the LEPR rs1137101 (A>G) polymorphism on obesity risk in Asian and Caucasian ethnicities. *Heliyon*. 2024;**10**(6):e27213. <https://doi.org/10.1016/j.heliyon.2024.e27213>
27. Yin D, Li Y, Liao X, Tian D, Xu Y, Zhou C, et al. FTO: a critical role in obesity and obesity-related diseases. *Br J Nutr*. 2023;**130**(10):1657–1664. <https://doi.org/10.1017/S0007114523000764>
28. Nead KT, Li A, Wehner MR, Neupane B, Gustafsson S, Butterworth A, et al. Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331,175 individuals. *Hum Mol Genet*. 2015;**24**(12):3582–3594. <https://doi.org/10.1093/hmg/ddv097>
29. Benzinou M, Chèvre JC, Ward KJ, Lecoœur C, Dina C, Lobbens S, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. *Hum Mol Genet*. 2008;**17**(13):1916–1921. <https://doi.org/10.1093/hmg/ddn089>
30. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694,649 individuals of European ancestry. *Hum Mol Genet*. 2019;**28**(1):166–174. <https://doi.org/10.1093/hmg/ddy327>
31. Wong HS, Tsai SY, Chu HW, Lin MR, Lin GH, Tai YT, et al. Genome-wide association study identifies genetic risk loci for adiposity in a Taiwanese population. *PLoS Genet*. 2022;**18**(1):e1009952. <https://doi.org/10.1371/journal.pgen.1009952>
32. Chiang KM, Chang HC, Yang HC, Chen CH, Chen HH, Lee WJ, et al. Genome-wide association study of morbid obesity in Han Chinese. *BMC Genet*. 2019;**20**(1):97. <https://doi.org/10.1186/s12863-019-0797-x>

33. Saeed S, Bonnefond A, Tamanini F, Mirza MU, Manzoor J, Janjua QM, et al. Loss-of-function mutations in ADCY3 cause monogenic severe obesity. *Nat Genet.* 2018;**50**(2):175–179. <https://doi.org/10.1038/s41588-017-0023-6>
34. Özcabi B, Durmaz A, Aykut A, Önal H, Özen S. A rare case of monogenic obesity due to a novel variant in the ADCY3 gene: challenges in follow-up and treatment. *J Clin Res Pediatr Endocrinol.* 2025;**17**(3):337–344. <https://doi.org/10.4274/jcrpe.galenos.2023.2023-7-2>
35. van der Klaauw AA, Croizier S, Mendes de Oliveira E, Stadler LKJ, Park S, Kong Y, et al. Human semaphorin 3 variants link melanocortin circuit development and energy balance. *Cell.* 2019;**176**(4):729–742.e18. <https://doi.org/10.1016/j.cell.2018.12.009>
36. Markham A. Setmelanotide: first approval. *Drugs.* 2021;**81**(3):397–403. <https://doi.org/10.1007/s40265-021-01470-9>
37. Pressley H, Cornelio CK, Adams EN. Setmelanotide: a novel targeted treatment for monogenic obesity. *J Pharm Technol.* 2022;**38**(6):368–373. <https://doi.org/10.1177/8755122522116010>
38. Kunasegaran T, Balasubramaniam VRMT, Arasoo VJT, Palanisamy UD, Ramadas A. Gestational diabetes mellitus in Southeast Asia: a scoping review. *Int J Environ Res Public Health.* 2021;**18**(3):1272. <https://doi.org/10.3390/ijerph18031272>
39. Tham KW, Abdul Ghani R, Cua SC, Deerochanawong C, Fojas M, Hocking S, et al. Obesity in South and Southeast Asia: a new consensus on care and management. *Obes Rev.* 2023;**24**(2):e13520. <https://doi.org/10.1111/obr.13520>
40. Dorajoo R, Blakemore AI, Sim X, Ong RT, Ng DP, Seielstad M, et al. Replication of 13 obesity loci among Singaporean Chinese, Malay and Asian-Indian populations. *Int J Obes (Lond).* 2012;**36**(1):159–163. <https://doi.org/10.1038/ijo.2011.86>
41. Zhao NN, Dong GP, Wu W, Wang JL, Ullah R, Fu JF. FTO gene polymorphisms and obesity risk in Chinese population: a meta-analysis. *World J Pediatr.* 2019;**15**(4):382–389. <https://doi.org/10.1007/s12519-019-00254-2>
42. Vasan SK, Karpe F, Gu HF, Brismar K, Fall CH, Ingelsson E, et al. FTO genetic variants and risk of obesity and type 2 diabetes: a meta-analysis of 28,394 Indians. *Obesity (Silver Spring).* 2014;**22**(3):964–970. <https://doi.org/10.1002/oby.20606>
43. Apalasy YD, Ming MF, Rampal S, Bulgiba A, Mohamed Z. Genetic association of SNPs in the FTO gene and predisposition to obesity in Malaysian Malays. *Braz J Med Biol Res.* 2012;**45**(12):1119–1126. <https://doi.org/10.1590/s0100-879x2012007500134>
44. Fan SH, Say YH. Leptin and leptin receptor gene polymorphisms and their association with plasma leptin levels and obesity in a multi-ethnic Malaysian suburban population. *J Physiol Anthropol.* 2014;**33**(1):15. <https://doi.org/10.1186/1880-6805-33-15>
45. Mohanraj J, D'Souza UJA, Fong SY, Karkada IR, Jaiprakash H. Association between leptin (G2548A) and leptin receptor (Q223R) polymorphisms with plasma leptin, BMI, stress, sleep and eating patterns among the multiethnic young Malaysian adult population from a healthcare university. *Int J Environ Res Public Health.* 2022;**19**(14):8862. <https://doi.org/10.3390/ijerph19148862>
46. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ.* 2020;**368**:l6890. <https://doi.org/10.1136/bmj.l6890>
47. Shunmugam V, Say YH. Evaluation of association of ADRA2A rs553668 and ACE I/D gene polymorphisms with obesity traits in the Setapak population, Malaysia. *Iran Red Crescent Med J.* 2016;**18**(2):e22452. <https://doi.org/10.5812/ircmj.22452>
48. Apalasy YD, Ming MF, Rampal S, Bulgiba A, Mohamed Z. Gender-dependent association of a  $\beta(2)$ -adrenergic gene variant with obesity parameters in Malaysian Malays. *Asia Pac J Public Health.* 2015;**27**(2):154–165. <https://doi.org/10.1177/1010539511430250>
49. Lek FY, Ong HH, Say YH. Association of dopamine receptor D2 gene (DRD2) Taq1 polymorphisms with eating behaviors and obesity among Chinese and Indian Malaysian university students. *Asia Pac J Clin Nutr.* 2018;**27**(3):707–717. <https://doi.org/10.6133/apjcn.092017.09>



50. Apalasamy YD, Rampal S, Salim A, Moy FM, Bulgiba A, Mohamed Z. Association of ADIPOQ gene with obesity and adiponectin levels in Malaysian Malays. *Mol Biol Rep.* 2014;**41**(5):2917–2921. <https://doi.org/10.1007/s11033-014-3147-0>
51. Apidi E, Sani A, Khairi Z, Johari Z, Izanwati R, Izanwati A, et al. Association of angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism with obesity and obesity-related phenotypes in Malay subjects. *Jordan J Biol Sci.* 2020;**13**(3):267–273.
52. Mitra SR, Tan PY, Amini F. Effect of FTO rs9930506 on obesity and interaction of the gene variants with dietary protein and vitamin E on C-reactive protein levels in multi-ethnic Malaysian adults. *J Hum Nutr Diet.* 2018;**31**(6):758–772. <https://doi.org/10.1111/jhn.12593>
53. Kok YY, Ong HH, Say YH. Interleukin-1 receptor antagonist and interleukin-4 genes variable number tandem repeats are associated with adiposity in Malaysian subjects. *J Obes.* 2017;**2017**:4104137. <https://doi.org/10.1155/2017/4104137>
54. Wan Rohani WT, Aryati A, Amiratul Athirah S. Haplotype analysis of leptin gene polymorphisms in obesity among Malays in Terengganu, Malaysia population. *Med J Malaysia.* 2018;**73**(5):281–285.
55. Lee KH, Chai VY, Kanachamy SS, Say YH. Association of UCP1 -3826A/G and UCP3 -55C/T gene polymorphisms with obesity and its related traits among multi-ethnic Malaysians. *Ethn Dis.* 2015;**25**(1):65–71.
56. Say YH, Ban ZL, Arumugam Y, Kaur T, Tan ML, Chia PP, et al. Uncoupling protein 2 gene (UCP2) 45-bp I/D polymorphism is associated with adiposity among Malaysian women. *J Biosci.* 2014;**39**(5):867–875. <https://doi.org/10.1007/s12038-014-9488-y>
57. Chia PP, Fan SH, Say YH. Screening of peroxisome proliferator-activated receptors (PPARs)  $\alpha$ ,  $\gamma$  and  $\alpha$  gene polymorphisms for obesity and metabolic syndrome association in the multi-ethnic Malaysian population. *Ethn Dis.* 2015;**25**(4):383–390. <https://doi.org/10.18865/ed.25.4.383>
58. Daya M, Pujianto DA, Witjaksono F, Priliani L, Susanto J, Lukito W, et al. Obesity risk and preference for high dietary fat intake are determined by FTO rs9939609 gene polymorphism in selected Indonesian adults. *Asia Pac J Clin Nutr.* 2019;**28**(1):183–191. [https://doi.org/10.6133/apjcn.201903\\_28\(1\).0024](https://doi.org/10.6133/apjcn.201903_28(1).0024)
59. Al-Jawadi AA, Priliani L, Oktavianthi S, Febinia CA, Daya M, Artika IM, et al. Association of FTO rs1421085 single nucleotide polymorphism with fat and fatty acid intake in Indonesian adults. *BMC Res Notes.* 2021;**14**(1):411. <https://doi.org/10.1186/s13104-021-05823-1>
60. Muhammad HFL, Sulistyoningrum DC, Huriyati E, Lee YY, Muda W. The interaction between energy intake, physical activity and UCP2 -866G/A gene variation on weight gain and changes in adiposity: an Indonesian nutrigenetic cohort (INDOGENIC). *Br J Nutr.* 2021;**125**(6):611–617. <https://doi.org/10.1017/S0007114520003104>
61. Martantiningtyas DC, Hastuti P, Sadewa AH. Leu72Met polymorphism of GHRL gene increase the risk factor of obesity in a Javanese ethnic group from Indonesia. *Meta Gene.* 2021;**29**:100912. <https://doi.org/10.1016/j.mgene.2021.100912>
62. Priliani L, Oktavianthi S, Hasnita R, Nussa HT, Inggriani RC, Febinia CA, et al. Obesity in the Balinese is associated with FTO rs9939609 and rs1421085 single nucleotide polymorphisms. *PeerJ.* 2020;**8**:e8327. <https://doi.org/10.7717/peerj.8327>
63. Hastuti P, Zukhrufia I, Padwaswari MH, Nuraini A, Sadewa AH. Polymorphism in leptin receptor gene was associated with obesity in Yogyakarta, Indonesia. *Egypt J Med Hum Genet.* 2016;**17**(3):271–276. <https://doi.org/10.1016/j.ejmhg.2015.12.011>
64. Utami RF, Hastuti P, Sadewa AH. RETN rs3745368 polymorphism and resistin level in Javanese ethnic Indonesian obese: a case control study. *J Teknol Laboratorium.* 2019;**8**(1):41–49. <https://doi.org/10.29238/teknolabjournal.v8i1.164>

65. Pramudji H, Demes CM, Dewi K, Tasmini T, Ahmad HS. Association of -174 G>C interleukin-6 gene polymorphism with interleukin-6 and C-reactive protein levels and obesity: a case-control study among people/residents of Western Indonesia. *Med J Malaysia*. 2019;74(5):400–404.
66. Surniyantoro HNE, Sadewa AH, Hastuti P. Uncoupling protein 2 (UCP2) as genetic risk factor for obesity in Indonesia is different in gender stratification. *Kobe J Med Sci*. 2018;64(2):E64–E72.
67. Oktavianthi S, Trimarsanto H, Febinia CA, Suastika K, Saraswati MR, Dwipayana P, et al. Uncoupling protein 2 gene polymorphisms are associated with obesity. *Cardiovasc Diabetol*. 2012;11:41. <https://doi.org/10.1186/1475-2840-11-41>
68. Binh TQ, Nakahori Y, Hien VTT, Khan NC, Lam NT, Mai LB, et al. Correlations between genetic variance and adiposity measures, and gene×gene interactions for obesity in postmenopausal Vietnamese women. *J Genet*. 2011;90:1–9. <https://doi.org/10.1007/s12041-011-0028-3>
69. Wells GA, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; 2011 [Retrieved 2024 Dec 22]. Available at: [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
70. Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: what have we learned about leptin and obesity? *Curr Opin Endocrinol Diabetes Obes*. 2015;22(5):353–359. <https://doi.org/10.1097/MED.0000000000000184>
71. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: role and clinical implication. *Front Endocrinol (Lausanne)*. 2021;12:585887. <https://doi.org/10.3389/fendo.2021.585887>
72. Chaves C, Kay T, Anselmo J. Early onset obesity due to a mutation in the human leptin receptor gene. *Endocrinol Diabetes Metab Case Rep*. 2022;21:024. <https://doi.org/10.1530/EDM-21-0124>
73. Karvonen MK, Pesonen U, Heinonen P, Laakso M, Rissanen A, Naukkarinen H, et al. Identification of new sequence variants in the leptin gene. *J Clin Endocrinol Metab*. 1998;83(9):3239–3242. <https://doi.org/10.1210/jcem.83.9.5135>
74. Maculewicz E, Leońska-Duniec A, Mastalerz A, Szarska E, Garbacz A, Lepionka T, et al. The influence of FTO, FABP2, LEP, LEPR, and MC4R genes on obesity parameters in physically active Caucasian men. *Int J Environ Res Public Health*. 2022;19(10):6030. <https://doi.org/10.3390/ijerph19106030>
75. Li WD, Reed DR, Lee JH, Xu W, Kilker RL, Sodam BR, et al. Sequence variants in the 5' flanking region of the leptin gene are associated with obesity in women. *Ann Hum Genet*. 1999;63(Pt 3):227–234. <https://doi.org/10.1046/j.1469-1809.1999.6330227.x>
76. Sabi EM, Bin Dahman LS, Mohammed AK, Sumaily KM, Al-Daghri NM. -2548G>A LEP polymorphism is positively associated with increased leptin and glucose levels in obese Saudi patients irrespective of blood pressure status. *Medicina (Kaunas)*. 2022;58(3):346. <https://doi.org/10.3390/medicina58030346>
77. Yiannakouris N, Melistas L, Yannakoulia M, Mungal K, Mantzoros CS. The -2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. *Hormones (Athens)*. 2003;2(4):229–236. <https://doi.org/10.14310/horm.2002.11104>
78. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. *Nat Rev Genet*. 2010;11(5):356–366. <https://doi.org/10.1038/nrg2760>
79. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*. 2016;538(7624):161–164. <https://doi.org/10.1038/538161a>
80. Zhang L, Yuan LH, Xiao Y, Lu MY, Zhang LJ, Wang Y. Association of leptin gene -2548 G/A polymorphism with obesity: a meta-analysis. *Ann Nutr Metab*. 2014;64(2):127–136. <https://doi.org/10.1159/000363392>



81. Nesrine Z, Haithem H, Imen B, Fadoua N, Asma O, Fadhel NM, et al. Leptin and leptin receptor polymorphisms, plasma leptin levels and obesity in Tunisian volunteers. *Int J Exp Pathol*. 2018;**99**(3):121–130. <https://doi.org/10.1111/iep.12271>
82. Chagnon YC, Wilmore JH, Borecki IB, Gagnon J, Pérusse L, Chagnon M, et al. Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE Family Study. *J Clin Endocrinol Metab*. 2000;**85**(1):29–34. <https://doi.org/10.1210/jcem.85.1.6263>
83. Huang C, Chen W, Wang X. Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases. *Genes Dis*. 2023;**10**(6):2351–2365. <https://doi.org/10.1016/j.gendis.2022.04.014>
84. Chey WW, Sook HF, Yee HS. Association of fat mass and obesity-associated (FTO) gene rs9939609 variant with obesity among multi-ethnic Malaysians in Kampar, Perak. *Sains Malaysiana*. 2013;**42**(3):365–371.
85. Susmiati S, Lipoeto NI, Surono IS, Jamsari J. Association of fat mass and obesity-associated rs9939609 polymorphisms and eating behaviour and food preferences in adolescent Minangkabau girls. *Pak J Nutr*. 2018;**17**:471–479. <https://doi.org/10.3923/pjn.2018.471.479>
86. Chang X, Dorajoo R, Sun Y, Han Y, Wang L, Khor C-C, et al. Gene-diet interaction effects on BMI levels in the Singapore Chinese population. *Nutr J*. 2018;**17**(1):31. <https://doi.org/10.1186/s12937-018-0340-3>
87. Pravednikova AE, Shevchenko SY, Kerchev VV, Skhirtladze MR, Larina SN, Kachaev ZM, et al. Association of uncoupling protein (UCP) gene polymorphisms with cardiometabolic diseases. *Mol Med*. 2020;**26**(1):51. <https://doi.org/10.1186/s10020-020-00180-4>
88. Sivenius K, Valve R, Lindi V, Niskanen L, Laakso M, Uusitupa M. Synergistic effect of polymorphisms in uncoupling protein 1 and  $\beta$ 3-adrenergic receptor genes on long-term body weight change in Finnish type 2 diabetic and non-diabetic control subjects. *Int J Obes Relat Metab Disord*. 2000;**24**(4):514–519. <https://doi.org/10.1038/sj.ijo.0801194>
89. Chathoth S, Ismail MH, Vatte C, Cyrus C, Al Ali Z, Ahmed KA, et al. Association of uncoupling protein 1 (UCP1) gene polymorphism with obesity: a case-control study. *BMC Med Genet*. 2018;**19**(1):203. <https://doi.org/10.1186/s12881-018-0715-5>
90. Sámano R, Huesca-Gómez C, López-Marure R, Hernández-Cabrera A-K, Rodríguez-Ventura A, Tolentino M, et al. Association between UCP polymorphisms and adipokines with obesity in Mexican adolescents. *J Pediatr Endocrinol Metab*. 2018;**31**(5):561–568. <https://doi.org/10.1515/jpem-2017-0262>
91. Liu X, Zhang B, Liu X, Shen Y, Li J, Zhao N, et al. A 45-bp insertion/deletion polymorphism in uncoupling protein 2 is not associated with obesity in a Chinese population. *Biochem Genet*. 2012;**50**(9-10):784–796. <https://doi.org/10.1007/s10528-012-9520-6>
92. Cassell PG, Neverova M, Janmohamed S, Uwakwe N, Qureshi A, McCarthy MI, et al. An uncoupling protein 2 gene variant is associated with a raised body mass index but not type II diabetes. *Diabetologia*. 1999;**42**(6):688–692. <https://doi.org/10.1007/s001250051216>
93. Mărginean CO, Mărginean C, Bănescu C, Meliț LE, Tripon F, Iancu M. The relationship between MMP9 and ADRA2A gene polymorphisms and mothers-newborns' nutritional status: an exploratory path model (STROBE compliant article). *Pediatr Res*. 2019;**85**(6):822–829. <https://doi.org/10.1038/s41390-019-0347-2>
94. Långberg EC, Seed Ahmed M, Efendic S, Gu HF, Östenson CG. Genetic association of adrenergic receptor alpha 2A with obesity and type 2 diabetes. *Obesity (Silver Spring)*. 2013;**21**(8):1720–1725. <https://doi.org/10.1002/oby.20162>
95. Albuquerque D, Nóbrega C, Manco L, Padez C. The contribution of genetics and environment to obesity. *Br Med Bull*. 2017;**123**(1):159–173. <https://doi.org/10.1093/bmb/ldxo22>